U.S. Markets closed

Allergan Stock Won’t Rise Much More, Analyst Says, in Looking at Deal With AbbVie

Josh Nathan-Kazis

Bernstein analyst Ronny Gal says the spread between the current stock price and AbbVie’s offer is fair and it is time to take the foot off the gas.